Seqirus, A CSL Company, 50 Hampshire Street, Cambridge, MA 02139, USA.
Seqirus, A CSL Company, 50 Hampshire Street, Cambridge, MA 02139, USA.
Vaccine. 2018 May 17;36(21):3010-3017. doi: 10.1016/j.vaccine.2018.04.021. Epub 2018 Apr 19.
Influenza vaccines are the most effective intervention to prevent the substantial public health burden of seasonal and pandemic influenza. The capability of hemagglutinin (HA), the main antigen in inactivated influenza vaccines (IIVs), to elicit functional neutralizing antibodies determines IIV effectiveness. When HA is subjected to environmental stress during manufacturing or while stored prior to administration, such as low pH and temperature excursions, the HA immunological activity can be affected. Single-radial immunodiffusion (SRID), the standard in vitro potency assay for IIVs, is believed to specifically detect immunologically active HA and has been applied to evaluate HA stability against stress. Here we report that transient low pH treatment and freeze/thaw cycles with HA in PBS abolish SRID-quantified in vitro potency for all HAs of multiple influenza strains. Raised temperature substantially decreases in vitro potency with more extensive HA structural changes. Chemical stress and mechanical stress moderately change SRID in vitro potency values in a strain-dependent manner. Trypsin digestion, which selectively degrades stressed HA, followed by RP-HPLC quantification as a candidate alternative in vitro potency assay yields results comparable to SRID. Mouse immunogenicity studies confirm that HA stressed by transient low pH treatment does not elicit functional antibodies in vivo, nor does it have a measureable SRID value. However, HA stressed by raised temperature elicits high titers of functional antibodies in vivo despite substantial loss of SRID in vitro potency. This discrepancy between SRID in vitro potency and vaccine immunogenicity suggests that SRID may not reliably indicate IIV potency under all conditions. Further efforts to develop alternate potency assays that can better predict in vivo immunogenicity should continue along with additional studies exploring HA conformation, SRID values and consequent immunogenicity.
流感疫苗是预防季节性和大流行性流感对公众健康造成重大负担的最有效干预措施。血凝素(HA)是灭活流感疫苗(IIV)中的主要抗原,其产生功能性中和抗体的能力决定了 IIV 的有效性。当 HA 在制造过程中或在给药前储存期间受到环境压力(如低 pH 值和温度波动)时,其免疫原性可能会受到影响。单向免疫扩散(SRID)是用于评估 IIV 针对压力的 HA 稳定性的标准体外效价测定方法,被认为可以特异性检测具有免疫活性的 HA。在这里,我们报告 PBS 中的 HA 经历短暂的低 pH 值处理和冻融循环会使所有流感株的 HA 的 SRID 定量体外效价丧失。升高的温度会导致 HA 发生更广泛的结构变化,从而大大降低体外效价。化学应激和机械应激以菌株依赖性的方式适度改变 SRID 体外效价值。胰蛋白酶消化,选择性降解应激 HA,然后进行反相高效液相色谱(RP-HPLC)定量分析,作为替代体外效价测定的候选方法,其结果与 SRID 相当。小鼠免疫原性研究证实,经历短暂低 pH 值处理的 HA 不会在体内诱导功能性抗体,也不会产生可测量的 SRID 值。然而,经历升高温度处理的 HA 会在体内引发高滴度的功能性抗体,尽管其体外效价 SRID 大大降低。SRID 体外效价与疫苗免疫原性之间的这种差异表明,在所有条件下,SRID 可能无法可靠地指示 IIV 效价。应继续努力开发可更好地预测体内免疫原性的替代效价测定方法,并进行更多研究以探索 HA 构象、SRID 值及其相应的免疫原性。